KLC2 and chronic myelogenous leukemia, BCR-ABL1 positive: As previously reported3–17, most CML-BC patients in our cohort acquired additional mutations, which not only included mutations previously reported in haematological malignancies and CML-BC, but also included previously unreported recurrent mutations, such as NBEAL2, PHIP, and KLC2 mutations.